Top

Published in:

Open Access 01-08-2014 | Research article

Evaluation of functional genetic variants at 6q25.1 and risk of breast cancer in a Chinese population

Authors: Yanru Wang, Yisha He, Zhenzhen Qin, Yue Jiang, Guangfu Jin, Hongxia Ma, Juncheng Dai, Jiaping Chen, Zhibin Hu, Xiaoxiang Guan, Hongbing Shen

Published in: Breast Cancer Research | Issue 4/2014

Abstract

Introduction

Single-nucleotide polymorphisms (SNPs) at 6q25.1 that are associated with breast cancer susceptibility have been identified in several genome-wide association studies (GWASs). However, the exact causal variants in this region have not been clarified.

Methods

In the present study, we genotyped six potentially functional single-nucleotide polymorphisms (SNPs) within the CCDC170 and ESR1 gene regions at 6q25.1 and accessed their associations with risk of breast cancer in a study of 1,064 cases and 1,073 cancer-free controls in Chinese women. The biological function of the risk variant was further evaluated by performing laboratory experiments.

Results

Breast cancer risk was significantly associated with three SNPs located at 6q25.1—rs9383935 in CCDC170 and rs2228480 and rs3798758 in ESR1—with variant allele attributed odds ratios (ORs) of 1.38 (95% confidence interval (CI): 1.20 to 1.57, P = 2.21 × 10^-6), 0.84 (95% CI: 0.72 to 0.98, P = 0.025) and 1.19 (95% CI: 1.04 to 1.37, P = 0.013), respectively. The functional variant rs9383935 is in high linkage disequilibrium (LD) with GWAS-reported top-hit SNP (rs2046210), but only rs9383935 showed a strong independent effect in conditional regression analysis. The rs9383935 risk allele A showed decreased activity of reporter gene in both the MCF-7 and BT-474 breast cancer cell lines, which might be due to an altered binding capacity of miR-27a to the 3' untranslated region (3' UTR) sequence of CCDC170. Real-time quantitative reverse transcription PCR confirmed the correlation between rs9383935 genotypes and CCDC170 expression levels.

Conclusions

The results of this study suggest that the functional variant rs9383935, located at the 3' UTR of CCDC170, may be one candidate of the causal variants at 6q25.1 that modulate the risk of breast cancer.

Available only for authorised users

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in, 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127: 2893-2917. 10.1002/ijc.25516.CrossRefPubMed

Linos E, Spanos D, Rosner BA, Linos K, Hesketh T, Qu JD, Gao YT, Zheng W, Colditz GA: Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J Natl Cancer Inst. 2008, 100: 1352-1360. 10.1093/jnci/djn305.CrossRefPubMedPubMedCentral

Ziegler RG, Anderson WF, Gail MH: Increasing breast cancer incidence in China: the numbers add up. J Natl Cancer Inst. 2008, 100: 1339-1341. 10.1093/jnci/djn330.CrossRefPubMed

Hirschhorn JN, Daly MJ: Genome-wide association studies for common diseases and complex traits. Nat Rev Genet. 2005, 6: 95-108. 10.1038/nrg1521.CrossRefPubMed

Division of Genomic Medicine, National Human Genome Research Institute, National Institutes of Health: A Catalog of Published Genome-Wide Association Studies. (accessed 22 August 2014)., [http://www.genome.gov/26525384]

Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, Wen W, Levy S, Deming SL, Haines JL, Gu K, Fair AM, Cai Q, Lu W, Shu XO: Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet. 2009, 41: 324-328. 10.1038/ng.318.CrossRefPubMedPubMedCentral

Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S, Ghoussaini M, Hines S, Healey CS, Hughes D, Warren-Perry M, Tapper W, Eccles D, Evans DG, Hooning M, Schutte M, van den Ouweland A, Houlston R, Ross G, Langford C, Pharoah PD, Stratton MR, Dunning AM, Rahman N, Easton DF: Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet. 2010, 42: 504-507. 10.1038/ng.586.CrossRefPubMedPubMedCentral

Long J, Cai Q, Sung H, Shi J, Zhang B, Choi JY, Wen W, Delahanty RJ, Lu W, Gao YT, Shen H, Park SK, Chen K, Shen CY, Ren Z, Haiman CA, Matsuo K, Kim MK, Khoo US, Iwasaki M, Zheng Y, Xiang YB, Gu K, Rothman N, Wang W, Hu Z, Liu Y, Yoo KY, Noh DY, Han BG, et al: Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer. PLoS Genet. 2012, 8: e1002532-10.1371/journal.pgen.1002532.CrossRefPubMedPubMedCentral

Hein R, Maranian M, Hopper JL, Kapuscinski MK, Southey MC, Park DJ, Schmidt MK, Broeks A, Hogervorst FB, Bueno-de-Mesquit HB, Muir KR, Lophatananon A, Rattanamongkongul S, Puttawibul P, Fasching PA, Hein A, Ekici AB, Beckmann MW, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Sawyer E, Tomlinson I, Kerin M, Miller N, Marmee F, Schneeweiss A, Sohn C, Burwinkel B, et al: Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS One. 2012, 7: e42380-10.1371/journal.pone.0042380.CrossRefPubMedPubMedCentral

10.

Zheng W, Zhang B, Cai Q, Sung H, Michailidou K, Shi J, Choi JY, Long J, Dennis J, Humphreys MK, Wang Q, Lu W, Gao YT, Li C, Cai H, Park SK, Yoo KY, Noh DY, Han W, Dunning AM, Benitez J, Vincent D, Bacot F, Tessier D, Kim SW, Lee MH, Lee JW, Lee JY, Xiang YB, Zheng Y, et al: Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls. Hum Mol Genet. 2013, 22: 2539-2550. 10.1093/hmg/ddt089.CrossRefPubMedPubMedCentral

11.

Stacey SN, Sulem P, Zanon C, Gudjonsson SA, Thorleifsson G, Helgason A, Jonasdottir A, Besenbacher S, Kostic JP, Fackenthal JD, Huo D, Adebamowo C, Ogundiran T, Olson JE, Fredericksen ZS, Wang X, Look MP, Sieuwerts AM, Martens JW, Pajares I, Garcia-Prats MD, Ramon-Cajal JM, de Juan A, Panadero A, Ortega E, Aben KK, Vermeulen SH, Asadzadeh F, van Engelenburg KC, Margolin S, et al: Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. PLoS Genet. 2010, 6: e1001029-10.1371/journal.pgen.1001029.CrossRefPubMedPubMedCentral

12.

Dai J, Hu Z, Jiang Y, Shen H, Dong J, Ma H: Breast cancer risk assessment with five independent genetic variants and two risk factors in Chinese women. Breast Cancer Res. 2012, 14: R17-10.1186/bcr3101.CrossRefPubMedPubMedCentral

13.

Thomas C, Gustafsson JA: The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011, 11: 597-608. 10.1038/nrc3093.CrossRefPubMed

14.

Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Jänicke F, Sauter G, Simon R: Estrogen receptor ? (ESR1) gene amplification is frequent in breast cancer. Nat Genet. 2007, 39: 655-660. 10.1038/ng2006.CrossRefPubMed

15.

Han J, Jiang T, Bai H, Gu H, Dong J, Ma H, Hu Z, Shen H: Genetic variants of 6q25 and breast cancer susceptibility: a two-stage fine mapping study in a Chinese population. Breast Cancer Res Treat. 2011, 129: 901-907. 10.1007/s10549-011-1527-x.CrossRefPubMed

16.

Qin Z, Xue J, He Y, Ma H, Jin G, Chen J, Hu Z, Liu X, Shen H: Potentially functional polymorphisms in ATG10 are associated with risk of breast cancer in a Chinese population. Gene. 2013, 527: 491-495. 10.1016/j.gene.2013.06.067.CrossRefPubMed

17.

Xu Z, Taylor JA: SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res. 2009, 37: W600-W605. 10.1093/nar/gkp290.CrossRefPubMedPubMedCentral

18.

Expression quantitative trait locus (eQTL) browser at the Pritchard lab. [] (accessed 22 August 2014)., [http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/]

19.

Zeller T, Wild P, Szymczak S, Rotival M, Schillert A, Castagne R, Maouche S, Germain M, Lackner K, Rossmann H, Eleftheriadis M, Sinning CR, Schnabel RB, Lubos E, Mennerich D, Rust W, Perret C, Proust C, Nicaud V, Loscalzo J, Hübner N, Tregouet D, Münzel T, Ziegler A, Tiret L, Blankenberg S, Cambien F: Genetics and beyond-the transcriptome of human monocytes and disease susceptibility. PLoS One. 2010, 5: e10693-10.1371/journal.pone.0010693.CrossRefPubMedPubMedCentral

20.

Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, Karczewski KJ, Park J, Hitz BC, Weng S, Cherry JM, Snyder M: Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 2012, 22: 1790-1797. 10.1101/gr.137323.112.CrossRefPubMedPubMedCentral

21.

Cai Q, Wen W, Qu S, Li G, Egan KM, Chen K, Deming SL, Shen H, Shen CY, Gammon MD, Blot WJ, Matsuo K, Haiman CA, Khoo US, Iwasaki M, Santella RM, Zhang L, Fair AM, Hu Z, Wu PE, Signorello LB, Titus-Ernstoff L, Tajima K, Henderson BE, Chan KY, Kasuga Y, Newcomb PA, Zheng H, Cui Y, Wang F, et al: Replication and functional genomic analyses of the breast cancer susceptibility locus at 6q25.1 generalize its importance in women of Chinese, Japanese, and European ancestry. Cancer Res. 2011, 71: 1344-1355. 10.1158/0008-5472.CAN-10-2733.CrossRefPubMedPubMedCentral

22.

Fletcher O, Johnson N, Orr N, Hosking FJ, Gibson LJ, Walker K, Zelenika D, Gut I, Heath S, Palles C, Coupland B, Broderick P, Schoemaker M, Jones M, Williamson J, Chilcott-Burns S, Tomczyk K, Simpson G, Jacobs KB, Chanock SJ, Hunter DJ, Tomlinson IP, Swerdlow A, Ashworth A, Ross G, dos Santos Silva I, Lathrop M, Houlston RS, Peto J: Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst. 2011, 103: 425-435. 10.1093/jnci/djq563.CrossRefPubMed

23.

Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Center JR, Nguyen TV, Bagger Y, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K: Multiple genetic loci for bone mineral density and fractures. N Engl J Med. 2008, 358: 2355-2365. 10.1056/NEJMoa0801197.CrossRefPubMed

24.

Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL, Ntzani EE, Oei L, Albagha OM, Amin N, Kemp JP, Koller DL, Li G, Liu CT, Minster RL, Moayyeri A, Vandenput L, Willner D, Xiao SM, Yerges-Armstrong LM, Zheng HF, Alonso N, Eriksson J, Kammerer CM, Kaptoge SK, Leo PJ, Thorleifsson G, Wilson SG, Wilson JF, Aalto V, Alen M, et al: Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012, 44: 491-501. 10.1038/ng.2249.CrossRefPubMedPubMedCentral

25.

Dunbier AK, Anderson H, Ghazoui Z, Lopez-Knowles E, Pancholi S, Ribas R, Drury S, Sidhu K, Leary A, Martin LA, Dowsett M: ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1. PLoS Genet. 2011, 7: e1001382-10.1371/journal.pgen.1001382.CrossRefPubMedPubMedCentral

26.

Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM: Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008, 76: 582-588. 10.1016/j.bcp.2008.06.007.CrossRefPubMedPubMedCentral

27.

Liu T, Tang H, Lang Y, Liu M, Li X: MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett. 2009, 273: 233-242. 10.1016/j.canlet.2008.08.003.CrossRefPubMed

28.

Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S: The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G₂-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 2007, 67: 11001-11011. 10.1158/0008-5472.CAN-07-2416.CrossRefPubMed

29.

Portal MM: MicroRNA-27a regulates basal transcription by targeting the p44 subunit of general transcription factor IIH. Proc Natl Acad Sci U S A. 2011, 108: 8686-8691. 10.1073/pnas.1014018108.CrossRefPubMedPubMedCentral

30.

Tang W, Zhu J, Su S, Wu W, Liu Q, Su F, Yu F: MiR-27 as a prognostic marker for breast cancer progression and patient survival. PLoS One. 2012, 7: e51702-10.1371/journal.pone.0051702.CrossRefPubMedPubMedCentral

31.

Li N, Dong J, Hu Z, Shen H, Dai M: Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010, 121: 177-184. 10.1007/s10549-009-0532-9.CrossRefPubMed

32.

Dunning AM, Healey CS, Baynes C, Maia AT, Scollen S, Vega A, Rodríguez R, Barbosa-Morais NL, Ponder BAJ, Low YL, Bingham S, Haiman CA, Le Marchand L, Broeks A, Schmidt MK, Hopper J, Southey M, Beckmann MW, Fasching PA, Peto J, Johnson N, Bojesen SE, Nordestgaard B, Milne RL, Benitez J, Hamann U, Ko Y, Schmutzler RK, Burwinkel B, Schürmann P, et al: Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet. 2009, 18: 1131-1139. 10.1093/hmg/ddn429.CrossRefPubMedPubMedCentral

33.

Klinge CM: Estrogen receptor interaction with co-activators and co-repressors. Steroids. 2000, 65: 227-251. 10.1016/S0039-128X(99)00107-5.CrossRefPubMed

34.

Sauna ZE, Kimchi-Sarfaty C: Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet. 2011, 12: 683-691. 10.1038/nrg3051.CrossRefPubMed

35.

Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, Maixner W, Diatchenko L: Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science. 2006, 314: 1930-1933. 10.1126/science.1131262.CrossRefPubMed

36.

Lian J, Tian H, Liu L, Zhang XS, Li WQ, Deng YM, Yao GD, Yin MM, Sun F: Downregulation of microRNA-383 is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation by targeting IRF1. Cell Death Dis. 2010, 1: e94-10.1038/cddis.2010.70.CrossRefPubMedPubMedCentral

Title: Evaluation of functional genetic variants at 6q25.1 and risk of breast cancer in a Chinese population
Authors: Yanru Wang
Yisha He
Zhenzhen Qin
Yue Jiang
Guangfu Jin
Hongxia Ma
Juncheng Dai
Jiaping Chen
Zhibin Hu
Xiaoxiang Guan
Hongbing Shen
Publication date: 01-08-2014
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 4/2014
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/s13058-014-0422-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2014

The influence of tamoxifen on normal mouse mammary gland homeostasis

Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone

Mammographic features associated with interval breast cancers in screening programs

Dual HER2 blockade: preclinical and clinical data

Keynote webinar | Spotlight on antibody–drug conjugates in cancer